NASDAQ:BSTC - BioSpecifics Technologies Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $66.51 +0.18 (+0.27 %) (As of 01/18/2019 04:00 PM ET)Previous Close$66.33Today's Range$66.35 - $67.6252-Week Range$38.05 - $68.00Volume62,744 shsAverage Volume51,550 shsMarket Capitalization$467.77 millionP/E Ratio39.19Dividend YieldN/ABeta1.26 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brand names. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York. Receive BSTC News and Ratings via Email Sign-up to receive the latest news and ratings for BSTC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:BSTC Previous Symbol CUSIP09093110 Webwww.biospecifics.com Phone516-593-7000Debt Debt-to-Equity RatioN/A Current Ratio48.43 Quick Ratio48.43Price-To-Earnings Trailing P/E Ratio39.19 Forward P/E Ratio26.60 P/E GrowthN/A Sales & Book Value Annual Sales$27.44 million Price / Sales17.64 Cash Flow$2.1101 per share Price / Cash Flow31.52 Book Value$9.39 per share Price / Book7.08Profitability EPS (Most Recent Fiscal Year)$1.70 Net Income$11.32 million Net Margins54.96% Return on Equity20.81% Return on Assets19.83%Miscellaneous Employees5 Outstanding Shares7,278,000Market Cap$467.77 million OptionableNot Optionable BioSpecifics Technologies (NASDAQ:BSTC) Frequently Asked Questions What is BioSpecifics Technologies' stock symbol? BioSpecifics Technologies trades on the NASDAQ under the ticker symbol "BSTC." How were BioSpecifics Technologies' earnings last quarter? BioSpecifics Technologies Corp. (NASDAQ:BSTC) released its earnings results on Friday, November, 9th. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.14. The biopharmaceutical company had revenue of $8.17 million for the quarter, compared to analyst estimates of $7.19 million. BioSpecifics Technologies had a return on equity of 20.81% and a net margin of 54.96%. View BioSpecifics Technologies' Earnings History. When is BioSpecifics Technologies' next earnings date? BioSpecifics Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, March 13th 2019. View Earnings Estimates for BioSpecifics Technologies. What price target have analysts set for BSTC? 1 brokerages have issued 1-year price targets for BioSpecifics Technologies' stock. Their predictions range from $81.00 to $81.00. On average, they expect BioSpecifics Technologies' stock price to reach $81.00 in the next year. This suggests a possible upside of 21.8% from the stock's current price. View Analyst Price Targets for BioSpecifics Technologies. What is the consensus analysts' recommendation for BioSpecifics Technologies? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioSpecifics Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioSpecifics Technologies. What are Wall Street analysts saying about BioSpecifics Technologies stock? Here are some recent quotes from research analysts about BioSpecifics Technologies stock: 1. According to Zacks Investment Research, "BIOSPECIFICS TECHNOLOGIES is engaged in the business of producing and licensing, for sale by other, a U.S. Food and Drug Administration (FDA) approved enzyme derived from collagenase, named Collagenase ABC, and researching, developing and clinically testing additional products derived therefrom for potential use as pharmaceuticals. " (1/17/2019) 2. HC Wainwright analysts commented, "Wegman, issued a letter to stakeholders of the company. Mr. Wegman has been diagnosed with glioblastoma and is undergoing treatment. However, based on our conversation with Mr. Wegman, we believe he is feeling good and optimistic about the therapy. There is limited impact on his work schedule and no disruption in the company’s ongoing operations. We note that Endo International (ENDP; not rated) continues to market Xiaflex (collagenase clostridium histolyticum, or CCH) for the treatment of Peyronie’s disease and Dupuytren’s contracture, and is slated to report top-line data from the Phase 3 trial of CCH for the treatment of cellulite in 1Q19. The cellulite pivotal data readout could be the next major catalyst for BioSpecifics, in our view. In the wake of this update, we reiterate our Buy rating and $65 price target. Phase 3 cellulite data in 1Q19." (7/5/2018) Has BioSpecifics Technologies been receiving favorable news coverage? News coverage about BSTC stock has trended somewhat negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioSpecifics Technologies earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. Who are some of BioSpecifics Technologies' key competitors? Some companies that are related to BioSpecifics Technologies include Myokardia (MYOK), Allakos (ALLK), Insmed (INSM), Corcept Therapeutics (CORT), Zogenix (ZGNX), PTC Therapeutics (PTCT), Madrigal Pharmaceuticals (MDGL), Portola Pharmaceuticals (PTLA), Mallinckrodt (MNK), Vanda Pharmaceuticals (VNDA), Pacira Pharmaceuticals (PCRX), Zai Lab (ZLAB), Prestige Consumer Healthcare (PBH), Theravance Biopharma (TBPH) and The Medicines (MDCO). Who are BioSpecifics Technologies' key executives? BioSpecifics Technologies' management team includes the folowing people: Mr. Thomas L. Wegman, CEO, Pres, Principal Financial Officer, Principal Accounting Officer, Sec. & Director (Age 63)Dr. Ronald Law, Sr. VP of Bus. Devel. (Age 65) Who are BioSpecifics Technologies' major shareholders? BioSpecifics Technologies' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Navellier & Associates Inc (0.06%). Company insiders that own BioSpecifics Technologies stock include Mark N Wegman, Of Edwin H Wegman Estate, Paul Gitman, Thomas Wegman and Toby Wegman. View Institutional Ownership Trends for BioSpecifics Technologies. Which major investors are buying BioSpecifics Technologies stock? BSTC stock was purchased by a variety of institutional investors in the last quarter, including Navellier & Associates Inc. View Insider Buying and Selling for BioSpecifics Technologies. How do I buy shares of BioSpecifics Technologies? Shares of BSTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BioSpecifics Technologies' stock price today? One share of BSTC stock can currently be purchased for approximately $66.51. How big of a company is BioSpecifics Technologies? BioSpecifics Technologies has a market capitalization of $467.77 million and generates $27.44 million in revenue each year. The biopharmaceutical company earns $11.32 million in net income (profit) each year or $1.70 on an earnings per share basis. BioSpecifics Technologies employs 5 workers across the globe. What is BioSpecifics Technologies' official website? The official website for BioSpecifics Technologies is http://www.biospecifics.com. How can I contact BioSpecifics Technologies? BioSpecifics Technologies' mailing address is 35 Wilbur Street, Lynbrook NY, 11563. The biopharmaceutical company can be reached via phone at 516-593-7000 or via email at [email protected] MarketBeat Community Rating for BioSpecifics Technologies (NASDAQ BSTC)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 192 (Vote Outperform)Underperform Votes: 133 (Vote Underperform)Total Votes: 325MarketBeat's community ratings are surveys of what our community members think about BioSpecifics Technologies and other stocks. Vote "Outperform" if you believe BSTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSTC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/18/2019 by MarketBeat.com StaffFeatured Article: What is the Quick Ratio?